Carcinoid Tumor

• EMA withdrawal · 2022-12-15
  EMA Withdrawn: IntronA (interferon alfa-2b) — Merck Sharp & Dohme B.V.

  The European Medicines Agency has withdrawn IntronA (interferon alfa-2b) from the market.

• CLINICAL_TRIALS withdrawal · 2017-08-23
  Clinical Trial Update: 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

  The clinical trial evaluating 68Ga DOTA-TATE PET/CT in somatostatin receptor–positive tumors is no longer available.